Hypertension Drugs Market size accounted 23837.88 billion in 2020 is estimated to reach 31419.46 billion by 2030 growing with a CAGR of 2.80% during the forecast periodHypertension are type of drugs which are used to treat hypertension (high blood pressure). Among the most significant and widely used medications are calcium channel blockers, thiazide diuretics, ACE inhibitors, beta blockers, and angiotensin II receptor antagonists (ARBs). There are three classes of diuretic drugs used to treat hypertension. Most commonly used are thiazide diuretics such as hydrochlorothiazide or chlorthalidone. ACE inhibitors (e.g., lisinopril, enalapril, ramipril): This class of medications works by blocking the body's production of a substance that tightens the blood vessels. Furthermore, when these muscles relax, the blood vessels become larger. Larger vessels mean more space for the blood inside the vessels and lower blood pressure.

Market Segmentation:

The global hypertension drugs market is bifurcated on the basis of analysis, systematic hypertension And Pulmonary hypertension. According to therapy the market is segmented into calcium channel blockers, diuretics, beta blockers vasodilators, angiotensin converting enzyme inhibitor, alpha blockers, angiotension receptor blockers and renin inhibitors. And on the basis of region the hypertension drugs market is segmented into North America, Europe, Asia-Pacific and RoW.

Market Dynamics and Factors:

Long term high blood pressure is one of the leading causes of heart failure, stroke, peripheral vascular diseases, chronic kidney diseases and other. High prevalence is the driver of hypertension drugs market. Social awareness campaigns by nonprofit and governmental organizations are likely to work in favor of the hypertension drugs market. For instance, the pulmonary hypertension offers education programs and has a strong support network which offers patients with right treatment information. In addition, rising demand for chronic diseases is also driven the market. Also the entry of generics which has driven the hypertension drugs market in upcoming forecast period. On the other hand, high incidence of side effects, there are drugs that act on region in the brain which control sympathetic autonomic overflow. There is high chance of side effects this will further restrain the hypertension drugs market growth.

Geographic Analysis:

North America dominates the global hypertension drugs market with almost 42% market share in 2018 due to the launch of new disease-modifying therapies. The immensely large amount of patients in Asia, Europe and Africa is in itself a huge hypertension drugs market driver and hold the opportunities for future relevance. The global hypertension drugs market size is expected to reach USD 33.1 billion by 2025.

Competitive Scenario:

The global hypertension drugs industry comprises of the following companies: Lupin Limited, Novartis AG, Sun Pharmaceuticals LLC, Daiichi - Sankyo, Pfizer Inc., Sanofi S.A, AstraZeneca Plc., Johnson & Johnson Ltd., Boehringer Ingelheim, and Merck & Co, Roche, Abbott, GlaxoSmithKline plc. AstraZeneca, Bayer AG, Gilead, and Actelion.

Hypertension Drugs Market Report Scope